Posted in | News | Nanomedicine

NanoSmart and UCLA Partner to Develop Nanotechnology-Based Cancer Drugs

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

"We are very excited to work closely with Dr. Noah Federman and his colleagues at UCLA, as they will provide access to an extraordinary level of research, development and clinical resources," said Dr. James Smith , President of NanoSmart Pharmaceuticals. "Their expertise in the development of nanotechnology-based drugs will enable us to continue making efficient progress towards commercializing these products."

NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of tumors. When combined with already FDA-approved cancer drugs, this patented technology allows for the creation of a broad range of next-generation, safer, and more effective cancer drug products.

"Despite the extensive research into new drug formulations, the pace of advancing benefit to this patient population is unfortunately slowing," said Dr. Noah Federman , Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, a part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center; and Assistant Professor of Pediatrics, Hematology/Oncology at Mattel Children's Hospital at UCLA. "We are pleased to collaborate with NanoSmart to help drive the development of these much-needed products."

Source: http://www.nanosmartpharma.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    University of California, Los Angeles. (2019, February 11). NanoSmart and UCLA Partner to Develop Nanotechnology-Based Cancer Drugs. AZoNano. Retrieved on January 28, 2023 from https://www.azonano.com/news.aspx?newsID=26359.

  • MLA

    University of California, Los Angeles. "NanoSmart and UCLA Partner to Develop Nanotechnology-Based Cancer Drugs". AZoNano. 28 January 2023. <https://www.azonano.com/news.aspx?newsID=26359>.

  • Chicago

    University of California, Los Angeles. "NanoSmart and UCLA Partner to Develop Nanotechnology-Based Cancer Drugs". AZoNano. https://www.azonano.com/news.aspx?newsID=26359. (accessed January 28, 2023).

  • Harvard

    University of California, Los Angeles. 2019. NanoSmart and UCLA Partner to Develop Nanotechnology-Based Cancer Drugs. AZoNano, viewed 28 January 2023, https://www.azonano.com/news.aspx?newsID=26359.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit